165 related articles for article (PubMed ID: 37183476)
1. A novel outlook in the delivery of artemisinin: production and efficacy in experimental visceral leishmaniasis.
Akbari M; Heli H; Oryan A; Hatam G
Pathog Glob Health; 2024 Feb; 118(1):40-46. PubMed ID: 37183476
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis.
Want MY; Islamuddin M; Chouhan G; Ozbak HA; Hemeg HA; Dasgupta AK; Chattopadhyay AP; Afrin F
Colloids Surf B Biointerfaces; 2015 Jun; 130():215-21. PubMed ID: 25936561
[TBL] [Abstract][Full Text] [Related]
3. Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis.
Want MY; Islammudin M; Chouhan G; Ozbak HA; Hemeg HA; Chattopadhyay AP; Afrin F
Int J Nanomedicine; 2017; 12():2189-2204. PubMed ID: 28356736
[TBL] [Abstract][Full Text] [Related]
4. A new approach for the delivery of artemisinin: formulation, characterization, and ex-vivo antileishmanial studies.
Want MY; Islamuddin M; Chouhan G; Dasgupta AK; Chattopadhyay AP; Afrin F
J Colloid Interface Sci; 2014 Oct; 432():258-69. PubMed ID: 25086720
[TBL] [Abstract][Full Text] [Related]
5. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of artemisinin in experimental visceral leishmaniasis.
Sen R; Ganguly S; Saha P; Chatterjee M
Int J Antimicrob Agents; 2010 Jul; 36(1):43-9. PubMed ID: 20403680
[TBL] [Abstract][Full Text] [Related]
7. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
8. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
11. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
[TBL] [Abstract][Full Text] [Related]
12. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
Freitas CS; Santiago SS; Lage DP; Antinarelli LMR; Oliveira FM; Vale DL; Martins VT; Magalhaes LND; Bandeira RS; Ramos FF; Pereira IAG; de Jesus MM; Ludolf F; Tavares GSV; Costa AV; Ferreira RS; Coimbra ES; Teixeira RR; Coelho EAF
Exp Parasitol; 2023 Aug; 251():108555. PubMed ID: 37247802
[TBL] [Abstract][Full Text] [Related]
14. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
Pinto EG; da Costa-Silva TA; Tempone AG
Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
[TBL] [Abstract][Full Text] [Related]
15. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.
Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R
Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
17. Exploring the repositioning of the amodiaquine as potential drug against visceral leishmaniasis: The in vitro effect against Leishmania infantum is associated with multiple mechanisms, involving mitochondria dysfunction, oxidative stress and loss of cell cycle control.
Antinarelli LMR; Midlej V; da Silva EDS; Coelho EAF; da Silva AD; Coimbra ES
Chem Biol Interact; 2023 Feb; 371():110333. PubMed ID: 36592711
[TBL] [Abstract][Full Text] [Related]
18. Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
Mendonça DVC; Tavares GSV; Pereira IAG; Oliveira-da-Silva JA; Ramos FF; Lage DP; Machado AS; Carvalho LM; Reis TAR; Carvalho AMRS; Ottoni FM; Ludolf F; Freitas CS; Martins VT; Chávez-Fumagalli MA; Duarte MC; Humbert MV; Roatt BM; Menezes-Souza D; Alves RJ; Coelho EAF
Exp Parasitol; 2022 Feb; 233():108205. PubMed ID: 34968460
[TBL] [Abstract][Full Text] [Related]
19. Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential.
Ribeiro JM; Rodrigues-Alves ML; Oliveira E; Guimarães PPG; Maria Murta Santi A; Teixeira-Carvalho A; Murta SMF; Peruhype-Magalhães V; Souza-Fagundes EM
Int Immunopharmacol; 2022 Sep; 110():108952. PubMed ID: 35716482
[TBL] [Abstract][Full Text] [Related]
20. Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro.
Allahverdiyev AM; Abamor ES; Bagirova M; Baydar SY; Ates SC; Kaya F; Kaya C; Rafailovich M
Exp Parasitol; 2013 Sep; 135(1):55-63. PubMed ID: 23792003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
